Clinical trial
BIOTRONIK - Safety and Clinical Performance of the - Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries
NCT04157153 is registered in ClinicalTrials.gov with Biotronik AG as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- BIOTRONIK - Safety and Clinical Performance of the - Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries
- Lead sponsor
- Biotronik AG
- Phase
- Not applicable
- Overall status
- Active, not recruiting
- Start date
- April 27, 2020
- Completion date
- February 28, 2027
- Enrollment
- 116 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.